

Journal of Visualized Experiments

Desthiobiotin-streptavidin-affinity mediated purification of RNA-interacting proteins in mesothelioma cells --Manuscript Draft--

Article Type:	Methods Article - JoVE Produced Video
Manuscript Number:	JoVE57516R2
Full Title:	Desthiobiotin-streptavidin-affinity mediated purification of RNA-interacting proteins in mesothelioma cells
Keywords:	RNA-binding protein; RNA-pulldown; non-coding RNA; 3'UTR; mesothelioma; Human-antigen R
Corresponding Author:	Emanuela Felley-Bosco Universitat Zurich Zurich, Zh SWITZERLAND
Corresponding Author's Institution:	Universitat Zurich
Corresponding Author E-Mail:	Emanuela.Felley-Bosco@usz.ch
First Author:	Jelena Kresoja-Rakic
Other Authors:	Jelena Kresoja-Rakic
Author Comments:	Dear Dr. Steindel, We have revised the ms according to Editorial comments. We hope that the manuscript is now suitable for publication. Sincerely yours Emanuela Felley-Bosco
Additional Information:	
Question	Response
If this article needs to be "in-press" by a certain date, please indicate the date below and explain in your cover letter.	

TITLE:

Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells

AUTHORS & AFFILIATIONS:

Jelena Kresoja-Rakic, Emanuela Felley-Bosco

Laboratory of Molecular Oncology, Division of Thoracic Surgery, University Hospital Zurich, Switzerland

CORRESPONDING AUTHOR:

Emanuela Felley-Bosco (Emanuela.felley-bosco@usz.ch)

Tel: +41 44 255 27 71

EMAIL ADDRESS OF CO-AUTHOR:

Jelena Kresoja-Rakic (jelena.kresoja@usz.ch)

KEYWORDS:

RNA-binding protein, RNA-pulldown, non-coding RNA, 3' UTR, mesothelioma, Human-antigen R

SUMMARY:

Desthiobiotin labeling of a synthetic 25-nucleotide RNA oligo, which contains an adenine-rich element (ARE) motif, allows specific binding of cytosolic ARE-binding protein.

ABSTRACT:

The *in vitro* RNA-pulldown is still largely used in the first steps of protocols aimed at identifying RNA-binding proteins that recognize specific RNA structures and motifs. In this RNA-pulldown protocol, commercially synthesized RNA probes are labeled with a modified form of biotin, desthiobiotin, at the 3' terminus of the RNA strand, which reversibly binds to streptavidin and thus allows elution of proteins under more physiological conditions. The RNA-desthiobiotin is immobilized through interaction with streptavidin on magnetic beads, which are used to pull down proteins that specifically interact with the RNA of interest. Non-denatured and active proteins from the cytosolic fraction of mesothelioma cells are used as the source of proteins. The method described here can be applied to detect the interaction between known RNA binding proteins and a 25-nucleotide (nt) long RNA probe containing a sequence of interest. This is useful to complete the functional characterization of stabilizing or destabilizing elements present in RNA molecules achieved using a reporter vector assay.

INTRODUCTION:

Gene expression and the final level of the gene product can be tightly regulated by affecting the mRNA stability and mRNA translation rate¹. These post-transcriptional regulatory mechanisms are exerted through the interactions of non-coding RNA and/or RNA-binding proteins (RBPs) with targeted mRNA. It is usually the 3' untranslated region of mRNA (3' UTR - belonging to the non-coding portion of the genome²) that contains specific *cis*-regulatory elements (CRE), which are

recognized by *trans*-acting factors such as miRNA or RBPs³. The best-studied *cis*-element within the 3' UTR, is the adenine-rich element (ARE) motif, which is recognized by specific AU-binding proteins (AUBP), and, in turn, induces either mRNA degradation/deadenylation (ARE-mediated decay) or mRNA stabilization⁴.

The size of the 3' UTR of calretinin mRNA (CALB2) is 573 bp long and contains a putative AUUUA pentamer, as predicted by AREsite2, a bioinformatic tool⁵. Consistent with the presence of a putative ARE motif, the pmirGLO vector-reporter assay demonstrated a stabilization role of this element within CALB2 mRNA⁶. Finally, the *in vitro* RNA-pulldown was used to identify the AUBP that stabilizes calretinin mRNA through the ARE motif.

Since all non-coding RNAs interact with proteins⁷, the *in vitro* RNA-pulldown is a good way and first-of-choice assay for identifying RNA-interactors to aid in deciphering molecular mechanisms. In this RNA-pulldown method, commercially synthesized RNA probes, which were labeled with a modified form of biotin (desthiobiotin) at the 3' terminus of the RNA strand, were used. The RNA-desthiobiotin is immobilized through interaction with streptavidin on magnetic beads, which are used to pull down proteins that specifically interact with the bound-RNA of interest. Non-denatured and active proteins from the cytosolic fraction of mesothelioma cells are used as the source of proteins. Such RNA-bound proteins are eluted from the magnetic beads, run through a 12% SDS-PAGE gel, transferred to a membrane, and probed with different antibodies.

In the standard streptavidin-biotin affinity purification procedure, harsh denaturation conditions are required to disrupt the strong irreversible biotin-streptavidin bond to elute the bound proteins⁸, which could lead to the dissociation of protein complexes. Unlike biotin, desthiobiotin reversibly binds to streptavidin and is competitively displaced with a buffered solution of biotin, allowing for the gentle elution of proteins, and avoiding the isolation of naturally biotinylated molecules⁹, suggesting that the technique is ideal for isolating native protein complexes under native conditions.

In vitro binding conditions and stringency, which are determined by salt concentration, reducing agents and detergent percentage, should be close to those present in the cellular context in order to identify true *in vivo* interactions. The binding conditions implemented herein have been previously demonstrated as appropriate for the identification of the HuR as an AU-binding protein¹⁰. This approach could save time, since optimization of proper binding conditions can be time-consuming and challenging. In addition, this method could be used as a starting protocol for any RNA-pulldown experiment and can be gradually optimized by changing the concentration of salts and detergents, changing the glycerol percentage, and adding other salts. Moreover, we demonstrated that even a short 25-nucleotide RNA-probe harboring a pentamer ARE-motif could be used to demonstrate interaction with a specific AUBP.

PROTOCOL:

1. Preparation of Cytosolic and Nuclear Protein Fraction

1.1. Plate 4×10^6 ACC-MESO-4 cells in a T150 cell culture flask grown in RPMI - 1640 medium supplemented with 10% FBS, 1x penicillin/streptomycin (100x), and 2 mM L-Glutamine (200 mM). When cells reach a confluence of 80-90% ($\sim 5\text{-}5.5 \times 10^6$ cells), proceed with protein extraction of nuclear and cytosolic fraction.

Note: ACC-MESO-4 cell line was obtained from the RIKEN BioResource Centre¹¹.

1.2. Aspirate medium, wash the cells by adding 15 mL of 1x PBS, tilt the plate gently a few times and aspirate the 1x PBS. Add 3 mL of 0.25% Trypsin-EDTA and incubate the culture flask at 37 °C for 3 min.

Note: Look at the cells under the microscope for detachment; if still attached tap the flask against the palm of a hand 3 times.

1.3. Add 7 mL of RPMI-1640 medium supplemented with 10% FBS, 1x penicillin/streptomycin (100x), and 2 mM L-Glutamine (200 mM), collect the cells in a 15 mL tube, and spin down at 200 x g for 5 min.

1.4. Aspirate medium and resuspend cell pellet with 1.5 mL of 1x PBS, then transfer the cells into a 1.5 mL microcentrifuge tube. Spin down at 500 x g and 4 °C for 5 min. Discard the supernatant.

Note: From this step onwards, perform all centrifugation steps at 4 °C and keep all reagents on ice.

1.5. Resuspend the cell pellet with ice-cold 1.5 mL of 1x PBS and spin down the cells at 500 x g and 4 °C for 3 min. Discard the supernatant.

Note: The required amounts of CER I, CER II, and NER reagents are 10, 0.55, and 5 volumes of estimated cell pellet packed volume, respectively; the following protocol assumes a volume of 50 μ L. We recommend preparing only the required amount of reagent CER I.

1.6. Add 500 μ L of ice-cold cytoplasmic extraction reagent (CER I) supplemented with 5 μ L of 1x proteinase inhibitor, *e.g.*, dilute 1 tablet of Protease Inhibitor (EDTA-free) in 500 μ L of water to obtain 100x stock. This amount of reagent CER I is enough to lyse 50 μ L of a cell pellet packed volume.

1.6.1. To estimate the cell pellet packed volume, compare the tube containing the cell pellet with a 1.5 mL tube filled with 10, 20, 50 or 100 μ L of 1x PBS.

1.7. Resuspend the cell pellet by vigorously vortexing the tube for 15 s and incubate the tube on ice for 10 min. Add 27.5 μ L of ice-cold cytoplasmic extraction reagent II (CER II) to the tube, vigorously vortex for 5 s, and incubate 1 min on ice.

1.8. Vortex vigorously for 5 s and centrifuge the tube at 16,000 x g and 4 °C for 5 min. Transfer the supernatant to the clean pre-chilled tube on ice. The supernatant is the cytoplasmic fraction that is further used in the RNA-pulldown experiment.

1.9. Resuspend the remaining pellet in 250 µL of ice-cold nuclear extraction reagent (NER) supplemented with 2.5 µL of proteinase inhibitor (100x) and vigorously vortex for 15 s. We recommend preparing only the required amount of NER reagent supplemented with protease inhibitors.

1.10. Incubate the sample on ice for 40 min with occasional vortexing for 15 s (every 10 min).

1.11. Centrifuge the tube at 16,000 x g for 10 min. Transfer the supernatant (this is the nuclear protein fraction) to a clean pre-chilled tube.

1.12. Immediately proceed by measuring protein concentration using the bicinchoninic (BCA) method (see **Table of Materials**). To control for protein purity of each fraction, perform immunoblotting (**Figure 1**) against α-tubulin (positive detection only in the cytosolic fraction) and Poly ADP-ribose polymerase - PARP (positive detection only in the nuclear fraction). For protein visualization, refer to section 4.

1.13. In order to keep protein activity and their native state, prepare 25 µL of aliquots of cytosolic and nuclear extracts. Snap-freeze these aliquots by placing them in liquid nitrogen for 5 s and store directly at -80 °C.

2. Labeling of RNA with Desthiobiotin

2.1. Have RNA probes commercially synthesized and HPLC purified. Resuspend with nuclease-free water at 10 µM.

Note: Probe sequences are listed in **Table 1**.

2.2. Use 50 pmol of RNA per RNA-pulldown reaction. Thaw and keep all reagents on ice except for PEG 30%, used to label 3' terminus of RNA oligo.

2.3. Transfer 5 µL of 10 µM RNA probes, labeled as CALB2 3' UTR (ARE), CALB2 3' UTR (mtARE), and Unrelated-RNA (IRE), into 0.5 mL thin-wall microcentrifuge tubes and incubate in a PCR machine at 85 °C for 5 min. Place the tubes immediately on ice.

Note: This step is important, as it promotes the relaxation and accessibility of the RNA probe for labeling.

2.4. For a single 30 µL reaction, add to the RNA-containing tube the following 10 µL mix: 3 µL of nuclease free water, 3 µL of 10x RNA Ligase Reaction Buffer, 1 µL of RNase Inhibitor (40 U/µL), 1 µL of Desthiobiotinylated Cytidine Bisphosphate (1 mM), and 2 µL of T4 RNA ligase (20 U/µL).

Note: To prepare master mix A for 3 samples in excess (3.2), mix 9.6 μL of nuclease free water, 9.6 μL of 10x RNA Ligase Reaction Buffer, 3.2 μL of RNase Inhibitor (40 U/ μL), 3.2 μL of Desthiobiotinylated Cytidine Bisphosphate (1 mM), and 6.4 μL of T4 RNA ligase (20 U/ μL).

2.5. Add carefully 15 μL of PEG 30% to the reaction. Use another tip to mix the reaction. Incubate the reaction overnight at 16 $^{\circ}\text{C}$.

2.6. The next day, prepare the following: 5 M NaCl (fresh/nuclease-free), chloroform: isoamyl alcohol in 24:1 ratio (*e.g.*, per reaction - 96 μL chloroform and 4 μL of isoamyl alcohol), ice-cold 100% ethanol, and ice-cold 70% ethanol.

2.7. Add 70 μL of nuclease-free water to the RNA-labeling reaction tubes. Add 100 μL of chloroform: isoamyl alcohol and vortex briefly. Spin-down at 13,000 x g for 3 min. Carefully remove ONLY the upper phase and transfer to a new nuclease-free 1.5 mL tube; avoid touching the lower phase.

2.8. Add 10 μL of 5 M NaCl, 1 μL of glycogen and 300 μL of ice-cold 100% ethanol. Place the tube at -20 $^{\circ}\text{C}$ for 2 h.

Note: At this step, the experiment can be continued on the following day.

2.9. Centrifuge at 13,000 x g and 4 $^{\circ}\text{C}$ for 15 min. Carefully discard the supernatant without disturbing the pellet. Add 300 μL of ice-cold 70% ethanol and centrifuge again at 13,000 x g and 4 $^{\circ}\text{C}$ for 5 min.

2.10. Discard the supernatant completely and air-dry the pellet (15 min). Resuspend the pellet in 20 μL of nuclease-free water.

Note: Proceed with RNA-pulldown on the same day.

2.11. Incubate the RNA at 90 $^{\circ}\text{C}$ for 2 min and place on ice. Place the labelled-RNA on ice during the following step of pre-washing of the streptavidin magnetic beads.

Note: A longer incubation time may damage the RNA probe.

3. RNA-Protein Pulldown

3.1. Pre-washing streptavidin-magnetic beads and incubation with desthiobiotin-RNA

3.1.1. Use 50 μL of streptavidin magnetic beads per 50 pmol RNA. However, this should be optimized depending on the experiment.

3.1.2. Vortex the tube with streptavidin-magnetic beads for 15 s, and quickly remove 200 μL

(master mix; enough for 3+1 reactions) into a clean 1.5 mL safe-lock tube using cut pipette tips. Place the tube on a magnetic stand so that the beads collect at the side of the tube and wait 1 min. Remove the resuspension liquid.

3.1.3. To wash the beads, remove the tube from the magnetic stand, add 400 μ L of 0.1 M NaOH, 0.05 M NaCl solution, and gently pipet up and down several times. Place the tube back on the magnetic stand. Wait 1 min and collect the supernatant. Repeat this step again.

3.1.4. Wash the beads with 200 μ L of 100 mM NaCl. Remove the supernatant.

3.1.5. Add 200 μ L of 20 mM Tris (pH 7.5), resuspend beads by pipetting, place the tube on the magnetic stand, wait for 1 min and remove the supernatant. Repeat the step.

3.1.6. Remove the tube from the magnetic stand, add 200 μ L of 1x RNA Capture buffer, and resuspend streptavidin magnetic beads by briefly vortexing. Remove 50 μ L of streptavidin magnetic beads and add to each labeled-RNA tube using a cut pipette tip. Incubate the tubes for 30 min at room temperature on a roller.

3.2. Binding of protein to RNA

3.2.1. Place the tubes into a magnetic stand, wait 1 min, and remove the supernatant.

3.2.2. Add 50 μ L of 20 mM Tris (pH 7.5) to the beads and resuspend by pipetting. Place the tubes into a magnetic stand, wait 1 min, and remove supernatant. Repeat this step.

3.2.3. Add 100 μ L of 1x Protein-RNA binding buffer to the beads and resuspend by pipetting.

3.2.4. In the meantime, prepare the following mix: 10 μ L of 10x Protein-RNA binding buffer, 30 μ L of 50% glycerol, 50 μ g of cytoplasmic proteins, and nuclease-free water up to 100 μ L.

Note: Prepare master mix B for 3 samples in excess (3.3) as follows: 33 μ L of 10x Protein-RNA binding buffer, 99 μ L of 50% glycerol, 165 μ g of cytoplasmic proteins and nuclease-free water up to 330 μ L. Keep the tube of master mix B on ice.

3.2.5. Place the tubes into magnetic stand, wait 1 min and collect the supernatant. Add 100 μ L of master mix B, resuspend by gently pipetting up and down, and avoid creating bubbles. Incubate reaction tubes for 60 min at 4 $^{\circ}$ C on a roller.

3.3. Washing and elution

3.3.1. Place the tubes into a magnetic stand, collect the supernatant (which is flow through - FT), and transfer into a new tube.

Note: Keep this FT on ice for later analysis.

3.3.2. Pipette 100 μ L of 1x Wash buffer on the beads, resuspend gently, put back into the magnetic stand, wait 1 min, and discard the supernatant. Repeat this step 2 times.

3.3.3. Add 40 μ L of Elution Buffer to the magnetic beads, mix by pipetting up and down, and incubate at 37 °C on a tube shaker (950 rpm) for 30 min.

3.3.4. Place the tubes into a magnetic stand, wait 1 min, and collect eluted sample (which is eluate - E). Place on ice and use for downstream analysis.

Note: At this step, each tested RNA probe consists of a flow-through (FT) and eluate (E) sample.

4. Polyacrylamide Electrophoresis and Western Blot Analysis

Note: See **Table 2** for recipes for the buffers used in this section. Perform a Western blot according to the Laemmli method¹².

4.1. Handcast 12% SDS-PAGE gels (10-wells, 1.5 mm spacer, 66 μ L). Prepare a running gel mix: 4 mL of 30% acrylamide–bisacrylamide stock solution, 2.4 mL of Lower Tris buffer, 3.2 mL of dH₂O, 9.6 μ L of TEMED, 96 μ L of 10% ammonium persulfate solution (APS). Prepare stacking gel mix: 3.25 mL of dH₂O, 0.5 mL of 30% acrylamide – bisacrylamide stock solution, 1.3 mL of Upper Tris buffer, 10 μ L of TEMED, 20 μ L of 10% APS.

4.2. Add 16.6 μ L of 6x Laemmli buffer (e.g., 14 mL of Tris/HCl/SDS pH 6.8 (Upper Tris buffer), 2 g of SDS, 1.86 g of DTT, 6 mL of glycerol, and 0.012% bromophenol blue; stored at -20 °C) into the FT sample, and 6.6 μ L of 6x Laemmli buffer into E sample. Incubate samples for 5 min at 95 °C.

4.3. Load the samples (20 μ L of FT and whole Elute ~40 μ L) and run them for 30 min at 60 V, continuing with 20 V overnight.

4.4. Using a semi-dry electroblotting system, transfer proteins onto a PVDF membrane for 80 min at 15 V.

Note: The PVDF membrane must be activated before performing protein transfer. Incubate the membrane in 100% methanol for 1 min, followed by a 2 min incubation in ultrapure water.

4.5. After the protein transfer, incubate the SDS-PAGE gel with Coomassie solution for 3 h, followed by three steps of washing with ultrapure water, each 30 min.

4.6. At the end of protein transfer, let the PVDF membrane dry for 1 h. Reactivate the membrane as indicated in step 4.5. Block the membrane 1 h with 5% BSA in 1x TTBS.

4.7. Incubate the membrane with the first antibody: HuR or mesothelin, both diluted 1:1000 in 5% BSA in 1x TTBS for 4h at room temperature or overnight at 4 °C.

4.8. Wash the membrane three times for 7 min in 1x TTBS, and incubate with rabbit anti-mouse horseradish peroxidase (HRP)-conjugated secondary antibody diluted 1:10,000 in 5% BSA, 1x TTBS.

4.9. Visualize proteins using enhanced chemiluminescence and a digital imager.

REPRESENTATIVE RESULTS:

In this experiment, a 25-nt long fragment of calretinin 3' UTR harboring ARE motif (CALB2 3' UTR (ARE) 25-nt) was used to test whether it binds specifically to the Human-antigen R (HuR) protein, a known mRNA stabilizer. To test the specificity of the ARE element, a 25-nt RNA probe CALB2 3' UTR (mtARE) containing an ARE-motif mutation, which was previously shown to abolish the stabilization effect of the ARE motif, was used⁶. The third RNA probe represents the negative control, which is a 28-nt unrelated RNA that contains the well-defined iron-responsive element (Unrelated RNA (IRE)), known to bind cytosolic iron-responsive protein^{13,14}. Since HuR is predominately localized within the nucleus but functions as a mRNA-stabilizer in the cytosol¹⁵, nuclear/cytosolic extraction was performed to obtain active proteins from the cytosol.

To demonstrate the purity of the nuclear/cytosolic fractions, proteins were analyzed by Western blot, which showed that α -tubulin was only detected in the cytosolic fraction, whereas PARP protein was detected only in the nuclear fraction, as anticipated (**Figure 1**). The eluate from the CALB2 3' UTR ARE-probe demonstrated binding of HuR whereas HuR was absent in the eluate from the mutant probe CALB 3' UTR (mtARE). HuR was also absent in the eluate from the unrelated RNA probe which binds the iron-responsive protein (**Figure 2A**). To further demonstrate the specificity between the CALB 3' UTR (ARE) and HuR, the membrane was additionally probed with anti-mesothelin (MSLN) antibody, as this protein does not interact with RNA. Eluates from all three samples showed no presence of mesothelin. Taken together, this indicates that the stabilizing ARE motif within CALB2 3'UTR can specifically bind HuR protein.

Coomassie staining of the gel (**Figure 2B**) shows that equal amounts of proteins were used to incubate with the three different RNA probes. Because of the low amount of cytosolic extract used and transfer to the membrane, this staining did not allow for detection of proteins in the eluate (E) lanes, which were otherwise detected by Western blot analysis.

FIGURE AND TABLE LEGENDS:

Figure 1. Western blot analysis of 5 μ g of cytosolic and nuclear protein fraction. PARP protein is present in the nuclear fraction (N) but absent from the cytosolic (C) fraction. α -tubulin is present in the cytosolic fraction (C) but absent in the nuclear fraction (N).

Figure 2. Western blot shows that HuR is captured by 25-nt CALB2 3' UTR (ARE). **A)** FT: flow through after incubation with RNA probe; E: proteins eluted upon incubation and binding to RNA probes. Probes: CALB2 3' UTR (mtARE) – 25-nt fragment of calretinin 3' UTR that contains 3 mutated nucleotides within the ARE motif; UR RNA (IRE) – 28-nt RNA probe with a well-defined

iron-responsive element that binds the iron-responsive proteins. The membrane was further probed for mesothelin (MSLN), a protein that does not interact with RNA. **B)** Coomassie staining of the gel after protein transfer, demonstrating that equal amounts of proteins were incubated with RNA probes.

Table 1: Sequences of RNA probes

Table 2: Recipes

DISCUSSION:

3' UTRs belong to the non-coding genome³, and all non-coding RNAs can interact with proteins in order to exert their function⁷. When the mammalian genome was found to be pervasively transcribed and produced a significant portion of long noncoding RNAs¹⁶, emerging evidences demonstrated that these long-noncoding RNAs function in regulating gene expression as they interact with chromatin-remodeling complexes¹⁷. This knowledge was gained by utilizing the RNA-pulldown assay. Thus, to start deciphering interactors of a specific RNA, the first step could be *in vitro* biochemical assays such as RNA-pulldown, as it is simple to perform.

Of note, not only sequence motifs but also the secondary structure of RNA plays a critical role in RNA functionality as they form domains essential for interacting with proteins. The secondary structure can vary in physiological and *in vitro* conditions, and RNA-pulldown may lead to the identification of false positives. For example, RNA-pulldown identified EZH2, a component of the polycomb repressive complex 2 (PRC2), as an interactor of X inactive specific transcript (*Xist*)¹⁸, whereas a recent study that used RNA antisense purification coupled with mass spectrometry (RAP-MS) identified other interactors such as SHARP (SMRT and HDAC associated repressor protein), SAF-1 (scaffold attachment factor A) and LBR (lamin B receptor)¹⁹. Therefore, if no other functional tests support the interaction between an RNA and a given protein, findings should be further supplemented with a complementary protein-centric approach, such as immunoprecipitating the given protein, followed by extraction and characterization of the bound RNA.

The herein protocol presented has been used to detect HuR binding to the ARE motif in CALB2 3' UTR, which had previously been functionally characterized by pmiRGLO-luciferase assay⁶. Due to the small amount of proteins, this protocol is not suitable for downstream analysis such as mass-spectrometry where larger protein amounts are necessary. Instead, the protocol can be used to revalidate the RNA-interactors identified by mass spectrometry, but using a significantly lower amount of proteins.

Since the method includes working with RNA, which is susceptible to degradation, we recommend cleaning the working surfaces with a RNase-decontaminating solution in addition to standard laboratory good practice. If possible, perform preparation of RNA labeling and purification under laminar flow. The purity of the RNA oligo may also affect the binding conditions; thus, the commercially synthesized probes were HPLC purified. If modified, longer and extremely pure RNA oligos are required, use PAGE purification method. Prepare aliquots of

native proteins by snap freezing, therefore avoiding damaging of proteins due to the slow freezing approach and repeated freezing and thawing.

ACKNOWLEDGMENTS:

This work was supported by the Swiss National Science Foundation Sinergia grant CRSII3 147697, the Stiftung für Angewandte Krebsforschung and Zürich Krebsliga.

DISCLOSURES:

The authors declare that they have no competing financial interests.

REFERENCES

- 1 Glisovic, T., Bachorik, J.L., Yong, J., & Dreyfuss, G. RNA-binding proteins and post-transcriptional gene regulation. *FEBS Letters*. **582** (14), 1977-1986, doi:10.1016/j.febslet.2008.03.004 (2008).
- 2 Mayr, C. Evolution and biological roles of alternative 3'UTRs. *Trends in Cell Biology*. **26** (3), 227-237, doi:10.1016/j.tcb.2015.10.012 (2016).
- 3 Matoulikova, E., Michalova, E., Vojtesek, B., & Hrstka, R. The role of the 3' untranslated region in post-transcriptional regulation of protein expression in mammalian cells. *RNA Biology*. **9** (5), 563-576, doi:10.4161/rna.20231 (2012).
- 4 von Roretz, C., Di Marco, S., Mazroui, R., & Gallouzi, I.E. Turnover of AU-rich-containing mRNAs during stress: a matter of survival. *Wiley Interdisciplinary Reviews: RNA*. **2** (3), 336-347, doi:10.1002/wrna.55 (2011).
- 5 Fallmann, J., Sedlyarov, V., Tanzer, A., Kovarik, P., & Hofacker, I.L. AREsite2: An enhanced database for the comprehensive investigation of AU/GU/U-rich elements. *Nucleic Acids Research*. **44** (D1), D90-95, doi:10.1093/nar/gkv1238 (2016).
- 6 Kresoja-Rakic, J. *et al.* Posttranscriptional regulation controls calretinin expression in malignant pleural mesothelioma. *Frontiers in Genetics*. **8** (70), doi:10.3389/fgene.2017.00070 (2017).
- 7 Chu, C., Spitale, R.C., & Chang, H.Y. Technologies to probe functions and mechanisms of long noncoding RNAs. *Nature Structural & Molecular Biology*. **22** (1), 29-35, doi:10.1038/nsmb.2921 (2015).
- 8 Diamandis, E.P. & Christopoulos, T.K. The biotin-(strept)avidin system: principles and applications in biotechnology. *Clinical Chemistry*. **37** (5), 625-636 (1991).
- 9 Hirsch, J.D. *et al.* Easily reversible desthiobiotin binding to streptavidin, avidin, and other biotin-binding proteins: Uses for protein labeling, detection, and isolation. *Analytical Biochemistry*. **308** (2), 343-357 (2002).
- 10 Thermo Scientific. Magnetic bead technology for better assay development. <https://assets.thermofisher.com/TFS-Assets/LSG/brochures/1602577-Magnetic-Bead-Technology-Brochure.pdf> (2013).
- 11 Usami, N. *et al.* Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. *Cancer Science*. **97** (5), 387-394, doi:10.1111/j.1349-7006.2006.00184.x (2006).
- 12 Laemmli, U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature*. **227** (5259), 680-685 (1970).

440 13 Coulson, R.M. & Cleveland, D.W. Ferritin synthesis is controlled by iron-dependent
441 translational derepression and by changes in synthesis/transport of nuclear ferritin RNAs.
442 *Proceedings of the National Academy of Sciences of the United States of America*. **90** (16),
443 7613-7617 (1993).

444 14 Leibold, E.A. & Munro, H.N. Cytoplasmic protein binds in vitro to a highly conserved
445 sequence in the 5' untranslated region of ferritin heavy- and light-subunit mRNAs.
446 *Proceedings of the National Academy of Sciences of the United States of America*. **85** (7),
447 2171-2175 (1988).

448 15 Srikantan, S. & Gorospe, M. HuR function in disease. *Frontiers in Bioscience (Landmark*
449 *Edition)*. **17**, 189-205 (2012).


450 16 Morris, K.V. & Mattick, J.S. The rise of regulatory RNA. *Nature Reviews: Genetics*. **15** (6),
451 423-437, doi:10.1038/nrg3722 (2014).

452 17 Rinn, J.L. *et al.* Functional demarcation of active and silent chromatin domains in human
453 HOX loci by noncoding RNAs. *Cell*. **129** (7), 1311-1323, doi:10.1016/j.cell.2007.05.022
454 (2007).


455 18 Zhao, J., Sun, B.K., Erwin, J.A., Song, J.J., & Lee, J.T. Polycomb proteins targeted by a short
456 repeat RNA to the mouse X chromosome. *Science*. **322** (5902), 750-756,
457 doi:10.1126/science.1163045 (2008).

458 19 McHugh, C.A. *et al.* The Xist lncRNA interacts directly with SHARP to silence transcription
459 through HDAC3. *Nature*. **521** (7551), 232-236, doi:10.1038/nature14443 (2015).


460



A



B



RNA probe	Sequence	Concentration
CALB2 3' UTR (ARE) 25nt	UCGCUGUAUGAUUUAGGCUUCUAUG	10 µM
CALB2 3' UTR (mARE) 25nt	UCGCUGUAUGGUCUGGGCUUCUAUG	10 µM
Unrelated RNA - IRE 28nt	UCCUGCUUCAACAGUGCUUGGACGGAAC	10 µM

Lower Tris buffer for running gel

1.5 M	Tris Base
0.40%	SDS solution
adjust pH to 8.8 using HCL (6 mol/L)	
fill up with	dH2O

Upper Tris for stacking gel SDS-PAGE

500 mM	Tris base
0.4%	SDS solution
Adjust pH to 6.8 using HCL (6 mol/L)	
fill up with	dH2O

10X Running buffer

250 mM	Tris base
1.92 M	Glycine
Adjust pH to 8.3 using HCL (6 mol/L)	
fill up with	dH2O
Filter or autoclave and store at 4°C	

1X Running buffer

100 mL	10X Running buffer
0.05%	SDS solution
Fill up to 1 L with	dH2O

10X Transfer Buffer

480 mM	Tris base
390 mM	Glycine
0.38%	SDS solution
fill up with	dH2O
Note: Filter 0.22 um and Store at 4°C	

1X Transfer buffer (for semi-dry system)

20 mL	10X Transfer Buffer
40 mL	methanol
fill up to 200 mL	dH2O

10X TBS (Tris-buffered saline)

250 mM	Tris base
1.36 M	NaCl
27 mM	KCl
Adjust pH to 7.4	
fill up with	dH2O
Filter	

1X TTBS (Tris-buffer saline with 0.1 Tween-20)

1X	10X TBS
0.10%	Tween-20
fill up with	dH2O

RNA Capture Buffer (1X)

20 mM	Tris (pH 7.5)
1 M	NaCl

1 mM	EDTA
Protein-RNA Binding Buffer (10x)	
200 mM	Tris (pH 7.5)
500 mM	NaCl
20 mM	MgCl ₂
1%	Tween-20
Wash Buffer (1x)	
20 mM	Tris (pH 7.5)
10 mM	NaCl
0.1%	Tween-20
Elution Buffer	
4 mM	biotin
20 mM	Tris (pH 7.5)
50 mM	NaCl
Coomassie solution	
0.02%	Coomassie G-250
5%	Aluminiumsulfate-(14-18)-hydrate
10%	EtOH
2%	ortho-phosphoric acid

Name of Material/ Equipment	Company	Catalog Number	Comments/Description
NE-PER Nuclear and cytoplasmic extraction kit	Thermo Fisher Scientific	78833	Includes magnetic beads and therefore the kit need to be stored at 4 °C The kit is a part of the "Pierce Magnetic RNA-protein Pull-Down Kit", and needs to be stored at -20 °C unlike the pull-down kit (4 °C).
Pierce Protease Inhibitor Tablets, EDTA-free	Thermo Fisher Scientific	A32965	
Pierce BCA Protein Assay Kit	Thermo Fisher Scientific	23225	
Pierce Magnetic RNA-protein Pull-Down Kit	Thermo Fisher Scientific	20164	
Pierce RNA 3' End Desthiobiotinylation Kit	Thermo Fisher Scientific	20163	
DynaMag-2, magnetic stand	Thermo Fisher Scientific	12321D	The antibody is included in the Pierce Magnetic RNA-protein Pull-Down Kit - - 1:1000 in 5% BSA 1x TTBS - rabbit anti-mouse secondary antibody 1:10,000 in 5% BSA 1x TTBS 1:1000 in 5% BSA 1x TTBS - rabbit anti-mouse secondary antibody 1:10,000 in 5% BSA 1x TTBS 1:1000 in 5% BSA 1x TTBS - goat anti-rabbit secondary antibody 1:10,000 in 5% BSA 1x TTBS
Anti - HuR (MOUSE) monoclonal antibody	Thermo Fisher Scientific		
Anti - α - tubulin (MOUSE) monoclonal antibody	Santa Cruz	8035	
Anti - PARP (RABBIT) Polyclonal antibody	Cell Signaling	9542	
Anti - Mesothelin (MOUSE) Monoclonal Antibody	Rockland	200-301-A87	
Secondary goat anti-rabbit antibody	Cell Signaling	7074	
Secondary rabbit anti-mouse antibody	Sigma-Aldrich	A-9044	
RPMI - 1640 medium	Sigma-Aldrich	R8758	
FBS - Filtrated Bovine Serum	Pan Biotech	P40-37500	
Penicillin - streptomycin (100x)	Sigma-Aldrich	P4333	
L-Glutamine solution (200 mM)	Sigma-Aldrich	G7513	
0.25% Trypsin-EDTA (1x)	Gibco by Life technologies	25200-056	
Mini-PROTEAN 3 Cell	Bio-Rad	1653301	
Mini Protean System Glass Plates	Bio-Rad	1653308	
Mini-PROTEAN Spacer Plates with 1.5 mm integrated spacer	Bio-Rad	1653312	
Mini-PROTEAN Comb, 10-well, 1.5 mm, 66 μ L	Bio-Rad	1653365	
Mini-PROTEAN Tetra Cell Casting Modules	Bio-Rad	1658050	
RNaseZap RNase Decontamination Solution	Thermo Fisher Scientific	AM9780	
Rotiphorese gel 30 - aqueous 30% acrylamide and bisacrylamide stock solution at a ration of 37.5:1	Roth	3029	
20% SDS	PanReac AppliChem	A3942	
PVDF transfer membrane	Perkin Elmer	NEF1002	Need to be activated by incubating in pure methanol for 1 min followed by washing in water for 2 min
Trans-Blot SD semi-dry transfer cell	Bio-Rad	1703940	
Clarity Western ECL Substrate	Bio-Rad	1705061	
FusionFX Digital Imager	Vilber	-	
RNA oligo synthesis	Mycrosynth AG, Switzerland	-	
Bovine serum albumin	Sigma-Aldrich	A7030	the synthesis scale - 0.04 μ mol - HPLC purified
Hydrochloric Acid (HCl) 6 M	PanReac AppliChem	182883.1211	
Ultra Pure 1 M Tris, pH 7.5	Thermo Fisher Scientific	15567027	
Glycerol	Thermo Fisher Scientific	17904	
Pierce Streptavidin magnetic beads	Thermo Fisher Scientific	88817	
TEMED	Sigma-Aldrich	T9281	Please note that these magnetic beads have an average diameter of 1 μ m (range from 0.5 - 1.5 μ m). Furthermore, Dynabeads-M280 Streptavidin, which are beads of homogenous size 2.8 μ m, are also used in RNA-pulldown but be aware that this may affect purification process.
Ammonium persulfate	Sigma-Aldrich	A3678	
Coomassie G-250	Applichem	A3480	
Aluminiumsulfate-(14-18)-hydrate	Sigma-Aldrich	368458	
ortho-phosphoric acid	Applichem	A0637	



1 Alewife Center #200
 Cambridge, MA 02140
 tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Desthiobiotin-streptavidin-affinity mediated purification of RNA-interacting proteins in mesothelioma cells

Author(s):

Jelena Kresoja-Rakic, Emanuela Felley-Bosco

Item 1 (check one box): The Author elects to have the Materials be made available (as described at

<http://www.jove.com/author>) via: ☒ Standard Access ☐ Open Access

Item 2 (check one box):

- ☒ The Author is NOT a United States government employee.
- ☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- ☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: “**Agreement**” means this Article and Video License Agreement; “**Article**” means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; “**Author**” means the author who is a signatory to this Agreement; “**Collective Work**” means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; “**CRC License**” means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; “**Derivative Work**” means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; “**Institution**” means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; “**JoVE**” means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; “**Materials**” means the Article and / or the Video; “**Parties**” means the Author and JoVE; “**Video**” means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the “Open Access” box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. Grant of Rights in Video – Open Access. This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. Likeness, Privacy, Personality. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have

ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's


expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

CORRESPONDING AUTHOR:

Name:	Emanuela Felley-Bosco		
Department:	Laboratory of Molecular Oncology		
Institution:	University of Zurich		
Article Title:	Desthiobiotin-streptavidin-affinity mediated purification of RNA-interacting proteins in mesothelioma cells		
Signature:	 Emanuela Felley-Bosco	Date:	30.10.2017

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email submissions@jove.com or call +1.617.945.9051

Dear Dr. Steindel,

We have revised the ms according to Editorial comments.

We hope that the manuscript is now suitable for publication.

Sincerely yours

Emanuela Felley-Bosco